#USA #Cardiovascular Health #Fountain Valley #MemorialCare #renal denervation

Introduction

In a remarkable advancement in cardiology, the MemorialCare Heart & Vascular Institute has begun offering a revolutionary minimally invasive treatment known as the Symplicity™ Renal Denervation (RDN) procedure. This cutting-edge therapy aims to assist patients grappling with resistant hypertension, a condition where blood pressure remains high despite the use of multiple medications. Notably, clinical trials have showcased this therapy's ability to reduce critical cardiovascular events by an impressive 20%, strokes by 27%, and heart failure instances by 28%.

Understanding Resistant Hypertension

Resistant hypertension affects approximately 10 million Americans, representing 17–20% of adults diagnosed with high blood pressure. This condition is prevalent among older adults and significantly impacts Black individuals, who are nearly 50% more likely to develop it compared to White adults. Moreover, patients with chronic conditions such as diabetes, chronic kidney disease, and obesity are at an elevated risk for this condition, which in turn heightens their susceptibility to life-threatening cardiovascular issues.

The Symplicity™ RDN Procedure

The RDN procedure targets the nerves surrounding the renal arteries, alleviating the communication disruption between the kidneys and the brain that contributes to high blood pressure. During the treatment, a thin, flexible catheter is strategically directed to the renal arteries through a minuscule incision made near the upper leg. Radiofrequency energy is then applied to specific areas of the artery wall, calming the overactive nerves without harming the arteries themselves.

Patients can typically return home the same day of the procedure, some after a short observation period, thereby avoiding the risks and complications associated with traditional surgeries and implants.

Clinical Evidence

Research from Medtronic indicates that a mere 10-mmHg decrease in systolic blood pressure can significantly reduce the occurrence of severe cardiovascular outcomes. The American Heart Association underscores the importance of managing resistant hypertension, claiming that it increases cardiovascular mortality by up to 56% compared to individuals with controlled blood pressure.

Dr. David Shavelle, chief of cardiology at MemorialCare, emphasizes that this innovative procedure not only enhances blood pressure control but does so in concert with existing treatment regimens. This aspect makes RDN a potentially life-altering option for those who have not had success with traditional therapies.

Community Commitment

MemorialCare's rollout of the RDN procedure across its healthcare facilities, including the Long Beach Medical Center, Orange Coast Medical Center, and Saddleback Medical Center, demonstrates a steadfast commitment to providing state-of-the-art cardiovascular care. This initiative is a part of a broader strategy aimed at making advanced therapies more accessible and significantly improving outcomes for patients facing complex cardiovascular issues.

Conclusion

The advent of the Symplicity™ Renal Denervation procedure represents a hopeful new chapter in the management of resistant hypertension and related cardiovascular risks. By harnessing this minimally invasive treatment, MemorialCare's Heart & Vascular Institute is not only enhancing patient care but also paving the way for innovative solutions in cardiovascular health. For more information about this cutting-edge procedure, individuals can visit memorialcare.org/Heart or reach out directly via phone.

About MemorialCare

MemorialCare is an integrated not-for-profit healthcare system in Southern California. With over 200 locations, it encompasses leading hospitals and promotes advanced healthcare services statewide, exemplifying its commitment to quality and community health.